Eli Lilly’s Alzheimer’s drug gets backing from FDA advisers
Eli Lilly’s experimental Alzheimer’s drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.
